BACKGROUND:Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults. Its primary active ingredient, Salvinorin A (SA)-a highly selective agonist at the κ opiate receptor-is believed to be one of the most potent naturally occurring hallucinogens. However, there is little experimental data on the effects of SA in humans. METHODS: In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiological, and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia. RESULTS:SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting electroencephalogram spectral power. The SA administration was associated with a rapid increase of its levels in the blood. SA did not produce euphoria, cognitive deficits, or changes in vital signs. The effects were transient and not dose-related. SA administration was very well-tolerated without acute or delayed adverse effects. CONCLUSIONS:SA produced a wide range of transient effects in healthy subjects. The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern. Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism. Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects.
RCT Entities:
BACKGROUND:Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults. Its primary active ingredient, Salvinorin A (SA)-a highly selective agonist at the κ opiate receptor-is believed to be one of the most potent naturally occurring hallucinogens. However, there is little experimental data on the effects of SA in humans. METHODS: In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiological, and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia. RESULTS:SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting electroencephalogram spectral power. The SA administration was associated with a rapid increase of its levels in the blood. SA did not produce euphoria, cognitive deficits, or changes in vital signs. The effects were transient and not dose-related. SA administration was very well-tolerated without acute or delayed adverse effects. CONCLUSIONS:SA produced a wide range of transient effects in healthy subjects. The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern. Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism. Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects.
Authors: A Maksimow; M Särkelä; J W Långsjö; E Salmi; K K Kaisti; A Yli-Hankala; S Hinkka-Yli-Salomäki; H Scheinin; S K Jääskeläinen Journal: Clin Neurophysiol Date: 2006-06-27 Impact factor: 3.708
Authors: Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Mauro Fà; Mario Manunta; Mara Puddu; Giampaolo Mereu; Gian Luigi Gessa Journal: Biol Psychiatry Date: 2005-06-15 Impact factor: 13.382
Authors: Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon Journal: Biol Psychiatry Date: 2008-07-17 Impact factor: 13.382
Authors: John E Mendelson; Jeremy R Coyle; Juan Carlos Lopez; Matthew J Baggott; Keith Flower; E Thomas Everhart; Thomas A Munro; Gantt P Galloway; Bruce M Cohen Journal: Psychopharmacology (Berl) Date: 2010-12-08 Impact factor: 4.530
Authors: M Salaga; P R Polepally; M Zielinska; M Marynowski; A Fabisiak; N Murawska; K Sobczak; M Sacharczuk; J C Do Rego; B L Roth; J K Zjawiony; J Fichna Journal: Br J Pharmacol Date: 2015-07-14 Impact factor: 8.739
Authors: C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman Journal: Psychopharmacology (Berl) Date: 2020-01-31 Impact factor: 4.530
Authors: Miguel Guerrero; Mariangela Urbano; Eun-Kyong Kim; Ana M Gamo; Sean Riley; Lusine Abgaryan; Nora Leaf; Lori Jean Van Orden; Steven J Brown; Jennifer Y Xie; Frank Porreca; Michael D Cameron; Hugh Rosen; Edward Roberts Journal: J Med Chem Date: 2019-02-13 Impact factor: 7.446
Authors: Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell Journal: J Pharmacol Exp Ther Date: 2020-09-10 Impact factor: 4.030